Alphamab Oncology
Alphamab Oncology's GHG Emissions Data Preview
In 2023, Alphamab Oncology completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, Alphamab Oncology has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2023 | 2022 | 2021 | 2020 - 2017 |
|---|---|---|---|---|
Total Scope 1 | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Total Scope 2 | ||||
Unspecified Calculation Method | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Total Scope 3 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 1 Revenue Intensity (tCO2e/$M) | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Verified Sources Behind Alphamab Oncology’s Greenhouse Gas (GHG) Emissions Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Alphamab Oncology’s data sources below and access millions more through our Disclosure Search.
Insights into Alphamab Oncology's Operational Emissions
In 2023, the total operational greenhouse gas (GHG) emissions of Alphamab Oncology amounted to 12,760.81 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2). a
Compared to 2022, the total operational greenhouse gas (GHG) emissions of Alphamab Oncology increased by 11.32%, suggesting that the company faced challenges in reducing its emissions from its core operations. a
Alphamab Oncology's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Alphamab Oncology's Scope 1 emissions?
In 2023, the total Scope 1 emissions of Alphamab Oncology were 3,969.51 metric tons of CO₂ equivalent (tCO₂e). a
Has Alphamab Oncology reduced its Scope 1 emissions over time?
Since 2020, Alphamab Oncology's Scope 1 emissions have increased by 76.47%, reflecting a rising long-term trend in Scope 1 emissions over time. a b
Compared to the previous year (2022), Alphamab Oncology's Scope 1 emissions increased by 10.1%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations. a
What are Alphamab Oncology's Scope 2 emissions?
In 2023, Alphamab Oncology reported Scope 2 greenhouse gas (GHG) emissions of 8,791.3 tCO₂e without specifying the calculation method. a
Has Alphamab Oncology reduced its Scope 2 emissions over time?
Since 2020, Alphamab Oncology's Scope 2 greenhouse gas (GHG) emissions ( Unspecified Calculation Method) have increased by 45.26%, reflecting a rising long-term trend in Scope 2 emissions over time. a b
Compared to the previous year (2022), Alphamab Oncology's Scope 2 emissions (Unspecified Calculation Method) rose by 11.89% in 2023, suggesting that the company faced challenges in reducing emissions from purchased electricity and energy a
What methodology does Alphamab Oncology use for Scope 2 reporting?
In 2023, Alphamab Oncology reported its Scope 2 emissions using an unspecified methodology. a
Alphamab Oncology's Scope 2 Emissions Over Time
- Total Scope 2 (Unspecified Calculation Method)
Insights into Alphamab Oncology’s GHG Emissions Intensity Compared to Industry Peers
In 2023, Alphamab Oncology reported Scope 1 greenhouse gas (GHG) emissions of 3,969.51 tCO₂e and total revenues of USD 34 millions. This translates into an emissions intensity of 117.9 tCO₂e per millions USD. a
Alphamab Oncology's Scope 1 Emissions Intensity Compared to Peers
How does Alphamab Oncology's GHG emissions intensity compare to its peers?
In 2023, Alphamab Oncology reported a Scope 1 emissions intensity of 117.9 tCO₂e per millions USD. Compared to the peer group median of 8.49 , this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors. a
Where does Alphamab Oncology rank on GHG emissions intensity within its industry?
In 2023, Alphamab Oncology ranked 24 out of 23 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD). a
This places Alphamab Oncology among the least efficient performers, with one of the highest emissions intensities in its sector. a